Abstract 142P
Background
Liquid biopsy is an emerging technology capable of detecting cancer, while CT-imaging is the gold standard. We aim to correlate imaging features from CT-scans to liquid biopsy ctDNA tumor fraction (TF) and blood Tumor Mutational Burden (bTMB).
Methods
This retrospective multicentric study included 1017 patients with metastatic cancer who underwent a variety of treatments. Liquid biopsy and contemporaneous CT-scans were collected. TF and bTMB values were computed using FoundationOne Liquid CDX solution by Roche, with high tumor fraction being over 10%. Two expert radiologists outlined all cancerous lesions in the largest axial diameter. Total tumor volume (TTV) was defined as the sum of estimated lesion volumes. Training set consisted of data from several imaging centers, while the validation set was single-center. Continuous value distributions by category were tested using the Mann-Whitney U-test, and a threshold was set with ROC curve analysis using Youden's Index. This cutoff defined high and low groups, and a Χ2 test of independence was used to examine the correlation. Sensitivity and specificity were reported with imaging features taken as the gold standard. Subanalyses were run on patients with liver lesions.
Results
Overall, 55294 lesions were annotated, most commonly located in the lung (n=20074), liver (n=11297) and lymph nodes (n=10222). The train and validation sets included 599 and 418 patients. Preliminary analyses were performed on the train set. Patients with low TF had significantly less TTV than those with high TF (p<0.001). ROC analysis yielded an AUC of 0.63 with a threshold of 106 cm3. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 76% and 42%. For patients with liver lesions (n=253) , TTV threshold was 108 cm3 with an AUC of 0.66. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 82% and 42%.
Conclusions
Analysis showed significant correlation between TTV and ctDNA TF. Sensitivity was higher for patients with liver lesions, suggesting that some organs shed tumoral DNA more than others. The study of tumor heterogeneity on imaging and its correlation to bTMB is in progress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
207P - Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Maged Khalil
Session: Poster session 01
208P - Identification of BCOR mutation as a novel predictor of immunotherapy efficacy in gastrointestinal tumors
Presenter: Wuping Wang
Session: Poster session 01
209P - Molecular atlas of copy number variation(CNV) in lung cancer with brain metastases
Presenter: Xianfeng Zhang
Session: Poster session 01
210P - Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery
Presenter: Andrea Riccardo Filippi
Session: Poster session 01
211P - Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Presenter: Evgeny Imyanitov
Session: Poster session 01
212P - Extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
Presenter: Si Sun
Session: Poster session 01
213P - Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Presenter: Hege Russnes
Session: Poster session 01
214P - PESSA: A shiny app for pathway enrichment score-based survival analysis in cancer
Presenter: Ying Shi
Session: Poster session 01
215P - Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Presenter: Camila Xavier
Session: Poster session 01
216P - PTCH1 mutation as a potential predictor of immune checkpoint inhibitors in gastrointestinal cancer
Presenter: Yang Tang
Session: Poster session 01